Kala Pharmaceuticals appoints Greg Perry to its Board of Directors

– USA, MA – Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Gregory Perry to the Company’s Board of Directors and Chair of its Audit Committee.

“We are pleased to welcome Greg to our board of directors and chair of our audit committee. Greg brings a wealth of business, strategic and financial expertise gained during his accomplished career in the biotech industry. We look forward to benefitting from his guidance as the company matures and we continue to advance toward commercialization,” said Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals.

Mr. Perry has served as Audit Committee Chair at Merus N.V. since 2016. He served as Chief Financial and Administrative Officer at Aegerion Pharmaceuticals Inc. from 2015 until the company’s merger with Novelion Therapeutics Inc., after which he served as Chief Financial and Administrative Officer at Novelion until 2017. Prior to joining Aegerion, Mr. Perry held the role of Chief Financial and Business Officer at Eleven Biotherapeutics, Inc. from 2014-2015. He was a member of the Board of Directors, Audit Committee Chair and Compensation Committee Member at Ocata Therapeutics, Inc. from 2011 until the company was acquired by Astellas Pharma Inc. in 2016. Prior to that, he served as Senior Vice President and Chief Financial Officer at ImmunoGen, Inc. from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role that he held until 2013. From 2002-2008, Mr. Perry served as Chief Financial Officer at a series of biotechnology companies including Elixir Pharmaceuticals, Inc., Domantis Ltd., Transkaryotic Therapies, Inc. and PerkinElmer Inc. Mr. Perry holds a Bachelor of Arts Degree in Economics and Political Science from Amherst College.

“This is an exciting time to join Kala’s Board of Directors and I am eager to work with the company as it continues to grow and develop innovative treatments for patients with eye diseases,” said Mr. Perry.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which the FDA has accepted for review Kala’s NDA submission and has established a PDUFA target action date of August 24, 2018, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

For more information : http://www.kalarx.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>